Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
21.17
+0.37 (1.78%)
Nov 26, 2025, 4:00 PM EST - Market closed
Dyne Therapeutics Employees
Dyne Therapeutics had 191 employees as of December 31, 2024. The number of employees increased by 50 or 35.46% compared to the previous year.
Employees
191
Change (1Y)
50
Growth (1Y)
35.46%
Revenue / Employee
n/a
Profits / Employee
-$2,218,853
Market Cap
3.02B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 191 | 50 | 35.46% |
| Dec 31, 2023 | 141 | 22 | 18.49% |
| Dec 31, 2022 | 119 | 26 | 27.96% |
| Dec 31, 2021 | 93 | 46 | 97.87% |
| Dec 31, 2020 | 47 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DYN News
- 6 days ago - Why Dyne Therapeutics Stock Was Crushing it This Week - The Motley Fool
- 22 days ago - Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 24 days ago - Dyne Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Why Dyne Therapeutics Stock Crushed the Market on Monday - The Motley Fool
- 4 weeks ago - This biotech's stock soared as investors look for the next buyout target - Market Watch
- 7 weeks ago - Dyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026 - Seeking Alpha
- 7 weeks ago - Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - GlobeNewsWire
- 2 months ago - Dyne Therapeutics Appoints Brian Posner to its Board of Directors - GlobeNewsWire